Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of ...
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
18h
Medical Device Network on MSNBrainomix concludes $18m fund raise to strengthen US presenceBrainomix entered the US market in 2023 having gained several FDA clearances for modules within its stroke care platform.
Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...
The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...
19h
Clinical Trials Arena on MSNNeurocrine Biosciences debuts new data for effectiveness of IngrezzaOf the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...
Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...
Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...
GlobalData on MSN6d
Boehringer Ingelheim and Salipro enter drug discovery partnershipThe partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results